Clinical Trials

INCB 18424-365 – A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation (REACH 3)


Research Study Number:
Pro2017-0535

Short Title:
REACH 3

Division:
Bone Marrow Transplant

Study Status:
Enrolling